SCHEMBL12427210

SCHEMBL12427210

CCCCCCCC/C=C\CCCCCCCC(=O)OCC1OC(O)C(O)C(O)C1O

nearest known ligand 0.60

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ DGKA P23743 1/20 0.48
▸ LPAR1 Q92633 1/20 0.47
▸ TLR4 O00206 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23432460 1.00 DGKA (0.48) DGKALPAR1TLR4
SCHEMBL2198730 1.00 DGKA (0.48) DGKALPAR1TLR4
SCHEMBL2198735 1.00 DGKA (0.48) DGKALPAR1TLR4
SCHEMBL13240137 1.00 DGKA (0.48) DGKALPAR1TLR4
SCHEMBL2198741 1.00 DGKA (0.48) DGKALPAR1TLR4
SCHEMBL13265734 0.99 DGKA (0.47) DGKALPAR1TLR4
SCHEMBL13240138 0.99 DGKA (0.47) DGKALPAR1TLR4
SCHEMBL2201777 0.96 — —
SCHEMBL12430969 0.96 — —
SCHEMBL2493311 0.96 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8729254-B2 Derivative of glucose and vitamin F, compositions comprising it, uses and preparation process L'OREAL (FR) 2014-05-20 — — US disclosed
US-8729254-B2 Derivative of glucose and vitamin F, compositions comprising it, uses and preparation process L'OREAL (FR) 2014-05-20 — — US disclosed
EP-1837341-B1 Derivative of glucose and vitamin F, compositions containing it, its uses to improve the state of hair OREAL (FR) 2011-08-03 — — EP disclosed
US-7977318-B2 Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process L'OREAL S.A. (FR) 2011-07-12 — — US disclosed
US-7795230-B2 Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process L'OREAL S.A. (FR) 2010-09-14 — — US disclosed
US-7795230-B2 Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process L'OREAL S.A. (FR) 2010-09-14 — — US disclosed
US-20090149396-A1 DERIVATIVE OF GLUCOSE AND VITAMIN F, COMPOSITIONS COMPRISING IT, USES AND PREPARATION PROCESS L'OREAL S.A. 2009-06-11 — — US disclosed
US-20090149396-A1 DERIVATIVE OF GLUCOSE AND VITAMIN F, COMPOSITIONS COMPRISING IT, USES AND PREPARATION PROCESS L'OREAL S.A. 2009-06-11 — — US disclosed
EP-1837341-A1 Derivative of glucose and vitamin F, compositions containing it, its uses and its preparation L'Oréal (FR) 2007-09-26 — — EP disclosed
EP-1371658-B1 Derivative of glucose and vitamin F, compositions containing it, its uses and its preparation OREAL (FR) 2007-09-12 — — EP disclosed
US-20070123471-A1 Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process L'OREAL S.A. 2007-05-31 — — US disclosed
US-20070123471-A1 Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process L'OREAL S.A. 2007-05-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149396-A1 DERIVATIVE OF GLUCOSE AND VITAMIN F, COMPOSITIONS COMPRISING IT, USES AND PREPARATION PROCESS FASN, ELOVL6, FADS2 DGKA 552/4885LPAR1 984/4885TLR4 2700/4885
US-20070123471-A1 Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process FASN, ELOVL6, ACSL6 DGKA 584/4885LPAR1 1124/4885TLR4 2674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback